Aims: To assess the non-inferiority of MYL-1501D, a proposed biosimilar or follow-on biological agent to marketed insulin glargine, to reference insulin glargine (Lantus ® ; Sanofi-Aventis US LLC, Bridgewater, New Jersey) based on change in glycated hemoglobin (HbA1c). Conclusions: Demonstration of non-inferiority between MYL-1501D and reference insulin glargine for reduction of HbA1c during 24 weeks of treatment was achieved. The two treatment groups were similar in terms of secondary endpoints, including hypoglycaemia and nocturnal hypoglycaemia, local and systemic reactions, other safety variables, and immunogenicity.
| INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a chronic disease characterized by insulin deficiency and resistance to the physiological effects of insulin, resulting in hyperglycaemia. 1, 2 Diabetes has been underrated as a global public health issue and, as diet and exercise patterns change worldwide, T2DM is becoming a global epidemic, with a prevalence rate in the developed world of >6% in 2000 and an estimated prevalence of >8% by the year 2030. Disease management is focused on control and reduction of hyperglycaemia, 3, 4 often through insulin. 5 Basal insulin is typically the initial insulin used for treatment of T2DM
and is commonly used in combination with oral antidiabetic drugs (OADs), glucagon-like peptide-1 receptor agonists, and, if needed, prandial insulin. 5 Conventional basal NPH insulin has pharmacodynamic limitations that predispose users to elevated glucose levels before breakfast as well as to nocturnal hypoglycaemia. 4 To overcome these challenges, basal insulin analogues (eg, insulin glargine 100 or 300 U/mL or detemir) 5 with modified amino acid sequences from human insulin have been developed that have 24-hour coverage to control fasting glucose levels. 4 Despite their use in various therapeutic conditions, biological agents such as insulin are costly, limiting access across the globe. [6] [7] [8] [9] [10] [11] [12] However, biosimilars and follow-on biologicals (FOBs) are beginning to enter the market, providing a larger variety of available agents at a lower cost. In the United States, the Food and Drug Administration (FDA) provides guidelines for the development of biosimilars and FOBs, which indicate that a biosimilar or FOB product should be highly similar to the biological reference product, with no clinically meaningful differences between the biosimilar or FOB and the reference product in terms of safety, purity and potency; minor differences in clinically inactive components are permissible. 13 Insulin glargine (Lantus ® ; Sanofi-Aventis US LLC, Bridgewater, New Jersey) is a long-acting human insulin analogue that can be administered once daily in adult patients with T2DM. 14 
MYL-1501D
is a proposed biosimilar/FOB with the same amino acid sequence as reference insulin glargine, and extensive comparative structural and functional characterization studies were performed to assess biosimilarity using orthogonal methods before proceeding with studies in humans. 15 
| MATERIALS AND METHODS

| Study design
This was a multicentre, open-label, randomized, parallel-group, phase III study comparing the efficacy and safety of MYL-1501D with reference insulin glargine in patients with T2DM receiving OADs ( Figure S1 ). Patients (who were not insulin-naive) were eligible for inclusion in the study if they had an established diagnosis of T2DM
(American Diabetes Association 2014 criteria) 17 for ≥1 year before screening, were on a stable dose of an OAD for ≥3 months before screening, were aged between 18 and 65 years, were receiving oncedaily insulin glargine at a stable dose for ≥3 months before screening, and had a glycated haemoglobin (HbA1c) concentration of <91 mmol/ mol. Insulin-naive patients (ie, patients who were never prescribed insulin on a regular basis) with an established diagnosis of T2DM were eligible if they were aged between 18 and 65 years and had an HbA1c concentration of >58 to ≤91 mmol/mol. All patients had to have a stable weight in the 3 months before screening and a body mass index between 18.5 and 40.0 kg/m 2 at screening.
After a 4-week screening period, patients were randomized in a (ADAs) and anti-host cell proteins were assessed for immunogenicity.
Blood samples for immunogenicity assessments were collected at pre- 3 | RESULTS
| Patient disposition and baseline characteristics
Overall, 951 patients were screened for enrolment in the study, and 391 patients failed screening for various reasons, including failure to meet the eligibility criteria, being outside the window for randomization, withdrawal of consent, and loss during follow-up before being randomized to treatment groups. In all, 560 patients were randomized to either the MYL-1501D (n = 277) or insulin glargine (n = 283) group for the 24-week treatment period ( Figure S2 ). Overall, 86.6% of patients (240/277) in the MYL-1501D group and 88.3% of patients (250/283) in the reference insulin glargine group completed the study.
The discontinuation rate for the total study population was 12.5%
(70 patients), with similar rates between the MYL-1501D and reference insulin glargine groups (13.4% vs 11.7%, respectively; P = 0.544). The most common reasons for discontinuation were with- MYL-1501D and reference insulin glargine groups, respectively ( Figure 1A and Table 2 ). The LS mean difference in change in HbA1c from baseline to week 24 between the two groups was 0.06% (95% CI −0.10, 0.22). The upper boundary of the 95% CI for mean change in HbA1c from baseline to week 24 was within the non-inferiority margin of 0.4%, indicating non-inferiority of MYL-1501D to reference insulin glargine. For patients who were insulin-naive, the LS mean (SE) change in HbA1c from baseline to week 24 was −1.01% (0.13) and −1.09% (0.13) for the MYL-1501D (n = 96) and reference insulin glargine (n = 98) groups, respectively ( Figure 1B and Table 2 ; 95% CI −0.19, 0.37; P = 0.528).
| Secondary endpoints
The mean (SD) change in FPG from baseline to week 24 was −0.74 Table 2 ]).
| Safety 3.3.1 | Adverse events
The incidence of TEAEs was generally similar between groups (P > 0.05; Table 3 ). In total, 64.1% of patients (177/276) receiving MYL-1501D and 58.2% (164/282) receiving reference insulin glargine experienced ≥1 TEAE during the 24-week treatment period (Table 3) .
Three patients in the MYL-1501D group experienced a total of six TEAEs (asthma, pleuritic pain, hypoxia, depression, headache, dyspepsia) that led to discontinuation of the study drug; no patients in the reference insulin glargine group discontinued treatment because of a TEAE. The most common TEAEs are shown in Table 3 . The TEAE profiles were similar in both insulin-naive and non-naive subgroups, although insulin-non-naive patients experienced a slightly higher 
| Hypoglycaemia
As noted above, hypoglycaemia was the most common TEAE in both treatment groups. Treatment-related hypoglycaemia was reported in 62 patients (22.5%) in the MYL-1501D group and 56 patients (19.9%) in the reference insulin glargine group. Overall, anytime and nocturnal hypoglycaemic rates (episodes/30 days) and incidence profiles were similar in the two treatment groups throughout the study (Figure 3 ).
No statistically significant differences were observed in hypoglycaemic rate or incidence profiles between groups at any visit. One patient in the reference insulin glargine group reported a severe nocturnal hypoglycaemic event at week 1, but no patients in the MYL-1501D group experienced a severe hypoglycaemic event during the study. Table 4 ]). The incidence of total ADAs (MYL-1501D, 25.4%; reference insulin glargine, 27.0%; P = 0.693) and insulin crossreactive antibodies (MYL-1501D, 26.1%; reference insulin glargine, 25.5%; P = 0.921) was also similar in the two treatment groups (Table 4 ).
| Immunogenicity
| DISCUSSION
In the present study, MYL-1501D demonstrated non-inferiority to reference insulin glargine for the primary endpoint of mean change in Despite these limitations, the findings from the present study support that MYL-1501D, which has already been approved by the EMA for use in the European Union, 16 is a biosimilar or FOB to insulin glargine, with efficacy and safety profiles similar to the reference product. Although non-inferiority to a licensed reference product is important for obtaining FDA 13 or EMA 19 approval as a biosimilar, the FDA requires additional switching studies to demonstrate interchangeability between a biosimilar and reference product, 20 whereas the EMA leaves the regulation of interchangeability up to the individual European Union member states. 19 The high price of biological agents has had an increasing impact on healthcare costs, but biosimilars, including MYL-1501D, are likely to be associated with cost savings and may help improve global access to treatment. 12, 21 Biosimilars that are designated as "interchangeable" according to the Biologics Price Competition and Innovation Act of 2009 are eligible for automatic substitution for the originator product, 22 which could help further improve cost savings and access to treatment. The interchangeability of MYL-1501D and reference insulin glargine is being assessed in a separate study and will be described in a separate publication.
In conclusion, the present study met its primary endpoint by demonstrating that mean change in HbA1c from baseline to week 24 was similar in patients with T2DM who were treated with MYL-1501D or reference insulin glargine, demonstrating the non-inferiority of MYL-1501D to the reference product. Overall, MYL-1501D was well tolerated, with no new safety signals compared with insulin glargine. Incidence of anytime and nocturnal hypoglycaemic events (self-monitored blood glucose ≤70 mg/dL) by visit and treatment group. BL, baseline
